Patent · US Active

Arenavirus particles as cancer vaccines

US11266727B2 · kind B2 · utility

3Cited by

8References

26Claims

0Family size

Assignee

Hookipa Biotech GmbH · AT

Inventors

Sarah Schmidt · Frankfurt, DE
Klaus Orlinger · Wien, AT
Katherine Cohen · Wien, AT

Key dates

Filing date	Nov 4, 2016
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Feb 5, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/5256
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.